Compare LNSR & CYPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LNSR | CYPH |
|---|---|---|
| Founded | 2004 | 2011 |
| Country | United States | United States |
| Employees | N/A | 6 |
| Industry | Medical Electronics | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.1M | 73.4M |
| IPO Year | 2005 | N/A |
| Metric | LNSR | CYPH |
|---|---|---|
| Price | $5.62 | $0.62 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | 90.2K | ★ 1.6M |
| Earning Date | 05-11-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | N/A |
| Revenue | ★ $58,435,000.00 | N/A |
| Revenue This Year | $10.06 | N/A |
| Revenue Next Year | $41.48 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 9.24 | N/A |
| 52 Week Low | $5.06 | $0.49 |
| 52 Week High | $13.32 | $3.70 |
| Indicator | LNSR | CYPH |
|---|---|---|
| Relative Strength Index (RSI) | 45.01 | 39.64 |
| Support Level | $5.58 | $0.58 |
| Resistance Level | $6.20 | $0.80 |
| Average True Range (ATR) | 0.21 | 0.06 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 27.91 | 2.88 |
LENSAR Inc is a commercial-stage medical device company focused on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts. The company Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, simplified procedure planning, efficient design, and precision. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. Geographically, the company generates the majority of its revenue from the United States, followed by Europe, Asia (excluding South Korea), South Korea, and Other.
Cypherpunk Technologies Inc is a privacy technology company focused on implementing a digital asset treasury business anchored by Zcash, which is a cryptographic digital asset that operates on a decentralized, open-source blockchain network known as the Zcash Network. Through its subsidiary, the company is also engaged in developing novel therapies for patients with cancer. The group holds Zcash as part of its digital treasury business and has the following drug candidates under development in its biopharma business: Sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1; and a preclinical antibody program, FL-501, that is designed to treat cachexia-related indications.